Senti Biosciences to Showcase Phase I SENTI-202 AML Safety and Activity Data
At the 11th Annual Innate Killer Conference, Senti Biosciences will present Phase I data from SENTI-202, an off-the-shelf, logic-gated CAR NK therapy demonstrating safety and preliminary anti-leukemic activity in relapsed/refractory AML patients. Analyses confirm selective CD33 and/or FLT3 targeting while sparing EMCN-expressing healthy cells, validating the logic-gated mechanism.
1. Conference Presentation Details
Senti Biosciences will present clinical and translational data from the ongoing Phase I SENTI-202 trial at the 11th Annual Innate Killer Conference, highlighting safety and preliminary anti-leukemic activity in adults with relapsed/refractory AML.
2. Clinical Data Highlights
The SENTI-202-101 study evaluates an off-the-shelf CAR NK cell therapy designed to target CD33 and/or FLT3 while sparing EMCN-expressing healthy cells, with early findings showing an acceptable safety profile and initial evidence of tumor cell reduction.
3. Translational Insights and Workshop
Correlative analyses to be presented confirm the therapy’s logic-gated mechanism of action, and a workshop led by the research team will explore biomarker discovery and translational approaches to advance NK cell therapy development.